Biosceptre

Australia - NorwestDiagnostics1 H-1B visas (FY2023)

Focus: Biosceptre is an Australian diagnostics and therapeutics company focused on nf-P2X7-targeted solutions, operating from Norwest with a specialized scientific focus.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biosceptre

AI assessmentNot Hiring

No open roles listed right now. Follow Biosceptre to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Treatment with BSCT

Carcinoma, Basal Cell (BCC)

Phase 1

Clinical Trials (1)

NCT02587819Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Phase 1

Help build intelligence for Biosceptre

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on a novel, underexplored target (nf-P2X7) with potential to establish proprietary position in emerging space
Australia-based operation may offer lifestyle and work culture advantages relative to US biotech hubs
Early-stage company offers potential equity upside and direct impact on scientific direction

Watch Out For

No active clinical trials (0 across all phases) indicates very early stage with unclear path to clinic and revenue
No public hiring activity (0 active job openings) suggests limited near-term expansion or may indicate resource constraints
Lack of disclosed funding, financials, and published data makes it difficult to assess company stability, capitalization, or scientific credibility

Generated by Claude from Biosceptre's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub